UK inhaled airways disease focused business Vectura Group (LSE: VEC) has announced a new collaboration with Jordan-headquartered Hikma Pharmaceuticals (LSE: HIK) for the development of generic salmeterol in the USA.
The agreement on Vectura’s generic salmeterol product, VR730, which has been signed by Hikma’s US affiliate, West-Ward Pharmaceuticals, builds on the existing partnership to develop a version of UK pharma major GlaxoSmithKline's (LSE: GSK) big-selling lung drug AdvairDiskus (fluticasone/salmeterol).
"VR730 has good market potential and is a logical expansion of our work on the existing generic programs with Hikma"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze